Epstein-Barr (EBV) Comprehensive Panel

The Epstein-Barr (EBV) Comprehensive Panel panel contains 2 tests with 4 biomarkers.

Brief Description: The Epstein-Barr (EBV) Comprehensive Panel is a collection of blood tests used to detect antibodies produced in response to an infection by the Epstein-Barr virus, a common herpesvirus that can cause infectious mononucleosis and is associated with several other health conditions. This panel is crucial for diagnosing EBV infections, understanding their stage, and assessing whether an infection is recent, reactivated, or past.

Collection Method: Blood Draw

Specimen Type: Serum

Test Preparation: No preparation required

When and Why the Epstein-Barr (EBV) Comprehensive Panel May Be Ordered

The Epstein-Barr (EBV) Comprehensive Panel may be ordered when a patient presents with symptoms suggestive of an EBV infection, such as fever, sore throat, swollen lymph nodes, fatigue, and malaise. It can also be ordered to help differentiate EBV infections from other conditions with similar symptoms or to assess the likelihood of a reactivation in individuals with a history of EBV-related conditions.

What the Epstein-Barr (EBV) Comprehensive Panel Checks For

Epstein Barr Virus Capsid IgM Antibody

The presence of VCA-IgM antibodies indicates a recent EBV infection. IgM antibodies are usually the first to appear in response to an infection, peaking within the first few weeks before declining.

Epstein Barr Virus Capsid IgG Antibody

VCA-IgG antibodies develop shortly after the IgM antibodies and usually remain in the body for life, indicating past exposure to EBV. The presence of these antibodies alone cannot distinguish between a recent and a past infection.

Epstein Barr Virus Nuclear Antigen IgG Antibody

EBNA-IgG antibodies appear several weeks after the initial EBV infection and persist for life. Their presence typically indicates a past infection, as these antibodies are not usually detectable during the acute phase of the disease.

Epstein Barr Virus Early Antigen D IgG Antibody

EA-D IgG antibodies are associated with the early phase of EBV infection and may also indicate a reactivation of the virus. These antibodies are usually only present in the acute phase and may decrease or disappear once the infection resolves.

Conditions or Diseases Detected by the Epstein-Barr (EBV) Comprehensive Panel

Infectious Mononucleosis

Often caused by EBV, infectious mononucleosis is characterized by fever, sore throat, swollen lymph glands, and fatigue. The panel can detect acute infection through VCA-IgM and early antigen antibodies and past infection through VCA-IgG and EBNA antibodies.

Chronic EBV Infection

In some cases, EBV can lead to a chronic infection, marked by persistent fatigue and other symptoms. The detection of EA-D antibodies, in particular, can suggest a reactivation of the virus or a chronic infection state.

EBV-Related Conditions

EBV is associated with several other conditions, including certain types of cancer such as Hodgkin's lymphoma and nasopharyngeal carcinoma, and autoimmune diseases like multiple sclerosis. While the panel cannot directly diagnose these conditions, abnormal antibody levels can indicate an underlying EBV infection that may be relevant to the patient's health status.

Using the Results in Treatment and Monitoring

Infectious Mononucleosis

For infectious mononucleosis, treatment is usually supportive, but the panel results can confirm the diagnosis and help rule out other conditions. Regular monitoring of antibody levels can help assess the resolution of the infection.

Chronic EBV Infection

In cases of chronic EBV infection, results can guide the management of symptoms and monitoring for complications. Persistent EA-D antibodies may warrant further evaluation and a more comprehensive management approach.

EBV-Related Conditions

For conditions potentially related to EBV, understanding the patient's EBV antibody profile can be an important part of the diagnostic puzzle, informing further testing and treatment strategies.

The Epstein-Barr (EBV) Comprehensive Panel is a critical tool in diagnosing and understanding EBV infections and their impact on health. By identifying the presence and type of antibodies produced in response to the virus, healthcare professionals can determine if an infection is recent, past, or reactivated, guiding appropriate treatment and monitoring strategies. This comprehensive approach helps ensure that patients receive timely and appropriate care for EBV-related conditions.

We advise having your results reviewed by a licensed medical healthcare professional for proper interpretation of your results.

The following is a list of what is included in the item above. Click the test(s) below to view what biomarkers are measured along with an explanation of what the biomarker is measuring.

Also known as: EBV, EBV Panel , Epstein Barr Virus (EBV) Panel, EpsteinBarr Virus EBV Antibody Panel

Ebv Nuclear Ag (Ebna)

Epstein-Barr virus (EBV) is a virus that typically causes a mild to moderate illness. These tests detect antibodies to EBV in the blood and help establish a diagnosis of an EBV infection. Epstein-Barr virus causes an infection that is very common. According to the Centers for Disease Control and Prevention (CDC), as many as 95% of people in the United States will have been infected by EBV by the time they are 40 years old.

Ebv Viral Capsid Ag (Vca)

Epstein-Barr virus (EBV) is a virus that typically causes a mild to moderate illness. These tests detect antibodies to EBV in the blood and help establish a diagnosis of an EBV infection. Epstein-Barr virus causes an infection that is very common. According to the Centers for Disease Control and Prevention (CDC), as many as 95% of people in the United States will have been infected by EBV by the time they are 40 years old.

Ebv Viral Capsid Ag (Vca)

Epstein-Barr virus (EBV) is a virus that typically causes a mild to moderate illness. These tests detect antibodies to EBV in the blood and help establish a diagnosis of an EBV infection. Epstein-Barr virus causes an infection that is very common. According to the Centers for Disease Control and Prevention (CDC), as many as 95% of people in the United States will have been infected by EBV by the time they are 40 years old.

Also known as: Ebv Early Antigen D Ab IgG

Ebv Early Antigen D

*Important Information on Lab Test Processing Times: Ulta Lab Tests is committed to informing you about the processing times for your lab tests processed through Quest Diagnostics. Please note that the estimated processing time for each test, indicated in business days, is based on data from the past 30 days across the 13 Quest Diagnostics laboratories for each test. These estimates are intended to serve as a guide and are not guarantees. Factors such as laboratory workload, weather conditions, holidays, and the need for additional testing or maintenance can influence actual processing times. We aim to offer estimates to help you plan accordingly. Please understand that these times may vary, and processing times are not guaranteed. Thank you for choosing Ulta Lab Tests for your laboratory needs.

Customer Reviews